company background image
HGEN.Q logo

Humanigen OTCPK:HGEN.Q Voorraadrapport

Laatste prijs

US$0.000001

Marktkapitalisatie

US$119.0

7D

-99.5%

1Y

-100.0%

Bijgewerkt

15 Jul, 2024

Gegevens

Financiële gegevens bedrijf

Humanigen, Inc.

OTCPK:HGEN.Q Voorraadrapport

Marktkapitalisatie: US$119.0

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

HGEN.Q Overzicht aandelen

A clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response.

Over het bedrijf

HGEN.Q fundamentele analyse
Sneeuwvlok Score
Waardering2/6
Toekomstige groei0/6
Prestaties in het verleden0/6
Financiële gezondheid1/6
Dividenden0/6

Beloningen

Risicoanalyse

Highly volatile share price over the past 3 months
Revenue has declined by 59% over the past year
Does not have a meaningful market cap ($119)
Negative shareholders equity

+ 2 meer risico's

Humanigen, Inc. Concurrenten

ObsEva

OTCPK:OBSE.F

US$11.7k

Mymetics

OTCPK:MYMX

US$151.0

Infinity Pharmaceuticals

OTCPK:INFI.Q

US$90.0

RegeneRx Biopharmaceuticals

OTCPK:RGRX

US$2.1k

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Humanigen
Historische aandelenkoersen
Huidige aandelenkoersUS$0.000001
52 Week HoogtepuntUS$0.21
52 Week LaagUS$0.000001
Bèta-1.34
11 maand verandering0%
3 maanden verandering0%
1 Jaar Verandering-100.00%
33 jaar verandering-100.00%
5 jaar verandering-100.00%
Verandering sinds IPO-100.00%

Recent nieuws en updates

Recent updates

Humanigen GAAP EPS of -$0.43 misses by $0.11, revenue of $1.04M beats by $0.69M

Aug 12

Humanigen plunges 57% as trial for COVID-19 therapy fails

Jul 13

Humanigen jumps over 10% after peer-reviewed data on COVID-19 therapy

Jul 06

Humanigen (NASDAQ:HGEN) Has Debt But No Earnings; Should You Worry?

Oct 30
Humanigen (NASDAQ:HGEN) Has Debt But No Earnings; Should You Worry?

Health Check: How Prudently Does Humanigen (NASDAQ:HGEN) Use Debt?

Jul 14
Health Check: How Prudently Does Humanigen (NASDAQ:HGEN) Use Debt?

Humanigen begins rolling submission for lenzilumab in COVID-19 in U.K.

Jun 14

Humanigen submits lenzilumab COVID-19 EUA application to FDA

May 28

Humanigen is on the rise after publication of Phase 3 data for COVID-19 therapy

May 05

Humanigen, Inc.'s (NASDAQ:HGEN) Intrinsic Value Is Potentially 61% Above Its Share Price

May 05
Humanigen, Inc.'s (NASDAQ:HGEN) Intrinsic Value Is Potentially 61% Above Its Share Price

We Might See A Profit From Humanigen, Inc. (NASDAQ:HGEN) Soon

Mar 31
We Might See A Profit From Humanigen, Inc. (NASDAQ:HGEN) Soon

Is Humanigen, Inc. (NASDAQ:HGEN) Popular Amongst Institutions?

Feb 26
Is Humanigen, Inc. (NASDAQ:HGEN) Popular Amongst Institutions?

Enrollment completed in Humanigen's late-stage study of lenzilumab in COVID-19

Jan 29

Humanigen partners with EVERSANA for launch and commercialization of Lenzilumab for COVID-19 treatment

Jan 11

We Think Humanigen (NASDAQ:HGEN) Can Afford To Drive Business Growth

Jan 04
We Think Humanigen (NASDAQ:HGEN) Can Afford To Drive Business Growth

Humanigen secures new U.S. patent for lenzilumab

Dec 28

Enrollment completed in Humanigen's early-stage ifabotuzumab study in glioblastoma multiforme

Dec 17

Humanigen EPS misses by $0.16

Nov 11

Humanigen up 7% on partnership with U.S. government to advance lenzilumab for COVID-19

Nov 06

Humanigen executes lenzilumab licensing deal in Asia for COVID-19

Nov 03

Humanigen Dosing Phase 3  Covid Patients, And Other News: The Good, Bad And Ugly Of Biopharma

Nov 01

Dosing underway in lenzilumab late-stage study in COVID-19

Oct 30

Dosing underway in mid-stage study of Humanigen's lenzilumab in COVID-19

Oct 29

Rendement voor aandeelhouders

HGEN.QUS BiotechsUS Markt
7D-99.5%-0.2%-0.4%
1Y-100.0%22.1%34.1%

Rendement versus industrie: HGEN.Q underperformed the US Biotechs industry which returned 14% over the past year.

Rendement versus markt: HGEN.Q underperformed the US Market which returned 22% over the past year.

Prijsvolatiliteit

Is HGEN.Q's price volatile compared to industry and market?
HGEN.Q volatility
HGEN.Q Average Weekly Movement102,515.4%
Biotechs Industry Average Movement10.0%
Market Average Movement6.4%
10% most volatile stocks in US Market14.9%
10% least volatile stocks in US Market3.1%

Stabiele aandelenkoers: HGEN.Q's share price has been volatile over the past 3 months.

Volatiliteit in de loop van de tijd: HGEN.Q's weekly volatility has increased from 50618% to 102515% over the past year.

Over het bedrijf

OpgerichtWerknemersCEOWebsite
20006Cameron Durrantwww.humanigen.com

Humanigen, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Humanigen zich tot de beurswaarde?
HGEN.Q fundamentele statistieken
MarktkapitalisatieUS$119.00
Inkomsten(TTM)-US$53.63m
Inkomsten(TTM)US$1.70m

0.0x

P/S-verhouding

0.0x

Koers/Winstverhouding

Is HGEN.Q overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
HGEN.Q resultatenrekening (TTM)
InkomstenUS$1.70m
Kosten van inkomstenUS$38.73m
Brutowinst-US$37.03m
Overige uitgavenUS$16.61m
Inkomsten-US$53.63m

Laatst gerapporteerde inkomsten

Mar 31, 2023

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)-0.45
Brutomarge-2,179.40%
Nettowinstmarge-3,156.80%
Schuld/Eigen Vermogen Verhouding0%

Hoe presteerde HGEN.Q op de lange termijn?

Bekijk historische prestaties en vergelijking